| Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 | Dec'16 | Sep'16 | Jun'16 | Mar'16 |
|---|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities: | |||||||||
Net earnings (loss) | |||||||||
-1,777,000 | -35,200 | 178,200 | 79,000 | 107,900 | -391,100 | -77,900 | 95,600 | 103,100 | 84,700 |
Adjustments to reconcile net loss to net cash flows provided by operating activities: | |||||||||
Depreciation and amortization | |||||||||
70,300 | 100,000 | 109,600 | 112,600 | 106,300 | 105,500 | 59,200 | 31,600 | 30,100 | 29,000 |
Amortization of deferred loan costs | |||||||||
4,400 | 4,300 | 4,400 | 4,400 | 4,200 | 4,200 | 2,800 | 2,200 | 2,100 | 2,100 |
Provision for uncollectibles | |||||||||
0 | 0 | 1,463,100 | 1,302,200 | 1,314,700 | 1,196,200 | 557,900 | 152,300 | 107,600 | 99,400 |
Net loss on disposals and deconsolidations | |||||||||
-800 | -1,000 | 6,400 | -3,300 | -5,800 | 300 | -1,000 | 4,100 | 2,600 | 0 |
Share-based compensation | |||||||||
8,800 | 7,400 | 8,300 | 11,100 | 13,200 | 16,100 | 8,200 | 6,100 | 7,900 | 7,200 |
Deferred income taxes | |||||||||
-2,500 | 27,900 | -1,056,100 | 45,400 | 25,100 | 504,200 | -113,500 | 13,600 | 14,400 | 6,600 |
Equity in earnings of unconsolidated affiliates | |||||||||
7,500 | 5,800 | 6,700 | 5,100 | 5,800 | 5,100 | 5,300 | 4,400 | 7,400 | 6,600 |
Impairment charges | |||||||||
1,979,900 | 700 | 500,000 | 0 | 0 | 300 | 221,300 | 0 | 0 | 0 |
Gain on held for sale assets | |||||||||
0 | 14,700 | - | - | 0 | 0 | - | - | - | - |
Other, net | |||||||||
- | - | - | - | - | - | 0 | 200 | 100 | 3,600 |
Increases (decreases) in cash, cash equivalents, restricted cash, and restricted cash equivalents net of acquisitions and dispositions: | |||||||||
Accounts receivable | |||||||||
8,300 | 40,500 | 1,443,800 | 1,433,800 | 1,334,700 | 1,243,200 | 615,300 | 159,400 | 113,800 | 114,500 |
Supplies inventory | |||||||||
0 | -200 | -1,300 | -400 | 0 | 700 | 200 | 300 | 200 | 200 |
Prepaid and other current assets | |||||||||
7,700 | 2,300 | 13,200 | -4,500 | 7,000 | -1,900 | 26,200 | -7,600 | 15,300 | 8,400 |
Accounts payable | |||||||||
8,700 | -22,600 | -5,100 | -900 | 2,800 | -8,900 | 4,000 | -2,300 | 2,800 | -6,100 |
Accrued expenses and other liabilities | |||||||||
-287,600 | 23,000 | -5,600 | 60,400 | 39,300 | -84,700 | 16,700 | 13,800 | -17,100 | -11,100 |
Other, net | |||||||||
-5,100 | 6,100 | 6,600 | 1,500 | -8,800 | -3,700 | -5,800 | -3,900 | -4,400 | -3,200 |
Net cash flows provided by operating activities | |||||||||
-12,600 | 37,300 | 236,400 | 182,300 | 280,600 | 98,100 | 68,800 | 156,000 | 113,300 | 81,700 |
Cash flows from investing activities: | |||||||||
Acquisitions and related expenses, net of cash acquired | |||||||||
56,900 | 71,600 | 63,400 | 208,700 | 412,600 | 73,100 | 42,600 | 70,600 | 278,100 | 3,000 |
Acquisition of property and equipment | |||||||||
33,500 | 45,300 | 70,400 | 47,800 | 50,000 | 40,700 | 35,500 | 26,400 | 21,900 | 15,700 |
Net proceeds from sale of medical transportation business | |||||||||
0 | 2,279,700 | - | - | 0 | 0 | - | - | - | - |
Purchases of marketable securities | |||||||||
8,600 | 57,300 | 5,800 | 2,800 | 12,500 | 3,400 | 1,100 | 0 | 500 | 0 |
Maturities of marketable securities | |||||||||
9,100 | 17,200 | 7,800 | 200 | 6,500 | 500 | 800 | 300 | 500 | 2,200 |
Other, net | |||||||||
12,400 | -1,100 | 1,700 | 15,500 | 6,000 | -17,300 | 2,800 | -2,200 | 7,200 | 1,500 |
Net cash flows provided by (used in) investing activities | |||||||||
-102,300 | 2,123,800 | -133,500 | -274,600 | -474,600 | -99,400 | 84,600 | -63,100 | -307,200 | -18,000 |
Cash flows from financing activities: | |||||||||
Proceeds from long-term borrowings | |||||||||
3,900 | 125,500 | 700 | 2,900 | 794,600 | 3,700 | 4,079,200 | 112,900 | 300,900 | 16,200 |
Repayment on long-term borrowings | |||||||||
3,500 | 1,824,200 | 13,700 | 13,700 | 302,400 | 11,900 | 3,847,800 | 115,500 | 58,500 | 40,300 |
Distributions to noncontrolling interests | |||||||||
60,000 | 53,100 | 55,500 | 55,300 | 58,500 | 60,500 | 55,800 | 56,500 | 58,800 | 56,800 |
Proceeds from issuance of common stock upon exercise of stock options | |||||||||
- | - | - | - | - | - | 200 | 0 | 200 | 300 |
Repurchase of common stock | |||||||||
- | - | - | - | - | - | 0 | 500 | 0 | 5,600 |
Other, net | |||||||||
-1,700 | -6,300 | -2,800 | 5,500 | -11,800 | -8,400 | -300 | -1,300 | -1,600 | 1,600 |
Net cash flows provided by (used in) financing activities | |||||||||
-61,300 | -1,758,100 | -70,000 | -69,500 | 421,900 | -77,100 | 72,100 | -60,900 | 182,200 | -84,600 |
Net increase (decrease) in cash, cash equivalents, and restricted cash | |||||||||
-176,200 | 403,000 | 32,900 | -161,800 | 227,900 | -78,400 | 225,500 | 32,000 | -11,700 | -20,900 |